COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP

• DOI: 10.1182/bloodadvances.2021005616
• Publication Date: 2021-11-08T23:51:20Z
• Authors: Alessandro Busca; Jon Salmanton-García; Paolo Corradini; Francesco Marchesi; Alba Cabirta; Roberta Di Blasi; Remy Dulery; Sylvain Lamure; Francesca Farina; Barbora Weinberge...; Josip Batinić; Anna Nordlander; Alberto López-García; Ľuboš Drgoňa; Ildefonso Espigad...; Iker Falces-Romero; Ramón García-Sanz; Carolina García-V...; Anna Guidetti; Nina Khanna; Austin Kulasekararaj; Johan Maertens; Martin Hoenigl; Nikolai Klimko; Philipp Koehler; Antonio Pagliuca; Francesco Passamonti; Oliver A. Cornely; Livio Pagano
• Keywords: T-Lymphocytes; Adoptive; :Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT]; COVID-19 (Malaltia); Immunotherapy, Adoptive; :terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS]; 03 medical and health sciences; 0302 clinical medicine; Receptors; :virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES]; Humans; :Cells::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::T-Lymphocytes [ANATOMY]; Receptors, Chimeric Antigen; Prevention; Teràpia cel·lular; Chimeric Antigen; COVID-19; :Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES]; Stimulus Report; 3. Good health; Good Health and Well Being; Cèl·lules T; Immunotherapy; Infection; :células::células sanguíneas::leucocitos::leucocitos mononucleares::linfocitos::linfocitos T [ANATOMÍA]

Key Points The EHA-IDWP developed an observational registry collecting data on COVID-19 infection in patients who received CAR T-cell therapy. Prevalence of COVID-19 was 4.8%, and overall mortality was 50%, highlighting the need for prevention of infection in these patients.